In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Pfizer's upcoming earnings report, and what the Big Pharma has in store for 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Foolish Preview: Pfizer Earnings
By Dave Williamson
–
Jan 28, 2013 at 8:09PM
NYSE: PFE
Pfizer
Market Cap
$136B
Today's Change
(0.40%) $0.10
Current Price
$23.98
Price as of June 20, 2025, 3:58 p.m. ET
What to expect from the big pharma's fourth quarter.
David Williamson owns shares of Pfizer. Follow him on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Pfizer
PFE
$23.98
(0.40%)
$0.10
Bristol Myers Squibb
BMY
$46.86
(0.04%)
$0.02
Incyte
INCY
$68.49
(0.32%)
$0.22
AbbVie
ABBV
$185.30
(-0.10%)
$0.19
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Top Stocks to Buy With Less Than $30
Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
Terrible News for Pfizer Stock Investors
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.